NVO - NeuroBo Pharmaceuticals Stock Slides Despite Animal Study Showing Wegvoy Liver Fibrosis Success | Benzinga
NeuroBo Pharmaceuticals Inc (NASDAQ:NRBO) shares were down more than 6% at last check Wednesday.
The Boston-based company announced preclinical data for its novel “G-Protein-Coupled Receptor 119 (GPR119) agonist,” known as DA-1241.
The data from a study on mice suggests that DA-1241 — combined with Novo Nordisk A/S’s (NYSE:NVO) semaglutide (Wegovy) — improves liver fibrosis. It also demonstrates additive hepatoprotective effects compared to either treatment alone.
DA-1241 did not influence liver weight, the company said.
In contrast, semaglutide reduced body weight by approximately 25% and improved hepatomegaly in GAN DIO-MASH mice with or without ...